Biogaia Ab Class B · OMXSTO:BIOG_B
Biogaia Ab Class B — Q3 2025 Earnings Presentation
18 slides from Biogaia Ab Class B's earnings presentation, Oct 22, 2025
Slide 1: Q3 2025 Results
Q3 2025 RESULTS Telephone Conference 22 October 2025 Theresa Agnew, CEO Alexander Kotsinas, CFO
Slide 2: Executive Summary Q3 2025
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Executive Summary Q3 2025 • Sales were 327 MSEK (+7%) due to higher sales in Americas and APAC, growth of 14% excluding currency effects • Sales in APAC increased by 17% an
Slide 3: BioGaia Strategy
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks BioGaia Strategy Expansion through Grow Direct Markets the Core Gut Health / Colic Oral Health Immune Health Breakthrough Innovation Foundations People & Culture Invest for
Slide 4: Delivering on Our Strategy
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Delivering on Our Strategy • Grow the Core – Driving growth of Pediatric and Adult segments – Investing in marketing and sales activities to drive strong growth in direct m
Slide 5: Launches
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Launches Distributor Country Product BioGaia Sweden BioGaia Aldermis probiotic ointment BioGaia Finland BioGaia Aldermis probiotic ointment BioGaia UK BioGaia Aldermis prob
Slide 6: Key Events
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Key Events • July 16: BioGaia announced that it launched BioGaia New Sciences AB – dedicated to advancing microbiome research and innovation • August 22: At an extraordinar
Slide 7: Sales per Segment
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales per Segment Sales per Segment Q3 2025 1% MSEK Q3 2025 Q3 2024 Change YTD 2025 YTD 2024 Change 25% Pediatrics 243 226 7% 823 823 0% Adult Health 82 77 6% 266 230 16% O
Slide 8: Sales per Region
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales per Region Sales per Region Q3 2025 MSEK Q3 2025 Q3 2024 Change YTD 2025 YTD 2024 Change EMEA 91 94 -4% 351 393 -11% 28% 45% APAC 90 77 17% 271 260 4% Americas 146 13
Slide 9: Financials
Alexander Kotsinas, CFO Financials 9
Slide 10: Key Financials
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Key Financials Sales (MSEK) Gross profit (MSEK) EBIT (MSEK) +9% 243 222 +7% 327 304 +108% 86 41 73% 74% 14% 26% Q3 2024 Q3 2025 Q3 2024 Q3 2025 Q3 2024 Q3 2025 10
Slide 11: Sales Bridge
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales Bridge +7% -20 327 304 43 Q3 2024 Organic Currency Q3 2025 growth effect Change 14% -7% 11
Slide 12: Gross Margin per Segment
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Gross Margin per Segment Gross margin Q3 2025 Q3 2024 YTD 2025 YTD 2024 Pediatrics 76% 75% 75% 76% Adult Health 69% 66% 67% 61% Total 74% 73% 73% 73% • Adult Health: gross
Slide 13: Operating Expenses (OPEX)
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Operating Expenses (OPEX) MSEK Q3 2025 Q3 2024 Change YTD 2025 YTD 2024 Change Sales and Marketing -116 -96 21% -367 -302 22% Research and Development -26 -71 -64% -79 -123
Slide 14: Profit and Loss Statement
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Profit and Loss Statement MSEK Q3 2025 Q3 2024 Change YTD 2025 YTD 2024 Change Sales 327 304 7% 1,098 1,058 4% Gross profit 243 222 9% 805 772 4% Percentage of revenue 74%
Slide 15: Cashflow
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Cashflow MSEK Q3 2025 Q3 2024 Change YTD 2025 YTD 2024 Change Cash flow from operating activities before 69 104 -34 241 350 -109 changes in net working capital Changes in w
Slide 16: Concluding Remarks
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Concluding Remarks Q3 2025 • The third quarter shows an overall sales increase of 7% (14% excluding foreign exchange effects) • The Pediatric segment grew 7% in the quarter
Slide 17: Q&A
Q&A
Slide 18: BioGaia
BioGaia.